Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
from Sanofi - Aventis Groupe https://ift.tt/wvpqhNI
via IFTTT
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
https://ift.tt/RnGcMUB
from Sanofi - Aventis Groupe https://ift.tt/wvpqhNI
via IFTTT
from Sanofi - Aventis Groupe https://ift.tt/wvpqhNI
via IFTTT
0 Comments
Please ,
Do not enter any kind of span link